C4 Therapeutics Company Insiders

C4 Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.2061) % which means that it has lost $0.2061 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.46) %, meaning that it created substantial loss on money invested by shareholders. C4 Therapeutics' management efficiency ratios could be used to measure how well C4 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of January 30, 2025, Return On Tangible Assets is expected to decline to -0.42. In addition to that, Return On Capital Employed is expected to decline to -0.5. At present, C4 Therapeutics' Asset Turnover is projected to slightly decrease based on the last few years of reporting. As of January 30, 2025, Common Stock Shares Outstanding is expected to decline to about 45 M. The current year's Net Loss is expected to grow to about (109.6 M)

C4 Therapeutics Workforce Comparison

C4 Therapeutics Insider Trading History

C4 Therapeutics Notable Stakeholders

The success or failure of an entity such as C4 Therapeutics often depends on how effective the management is. C4 Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CCCC management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CCCC management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the presentation of C4 Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, C4 Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of C4 Therapeutics' management manipulating its earnings.

When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.